SCALE-UP CONFERENCE

Taking Aflasafe from Science to Scale
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Importance of aflatoxins
Aflatoxin Bl

Occurrence
40% of commodities in
local markets exceed ML

Susceptible crops
Maize, groundnuts, sorghum,
cottonseed, chili, millet, figs,
melon seed, ginger, sesame,
cassava, almond, pistachio ...

GrO<Jndnut exports
in metric tons

99.59%
decrease
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51,450

48.23%
~~rease

Biocontrol is a simple field intervention that effectively reduces
aflatoxin contamination from farms until consumption
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Proof of Conce t

32 agribusinesses
49,500 farmers
63,000 ha maize grown
600 tons Aflasafe
purch Grain lots (n = 2,362) with
aflatoxin concentration

194,310 tons of grains
harvested
• 57°/o aggregated for sale
• 27% consumed at ho ~ • 16% sold in local mar

%

Productivity: 3.1
tons/ha compared to
1.5 tons/ha national
average
Meets
international
------ standards

-----------

• 10. 7% premium in
the market over
normal maize
• $1.491 million in net
earning from
.
premium
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Commerc1a
· 1·1zat·10n Pa th
YEARl

1· Design of

Commerdallzatlon
Strateay
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YEAR 2-3

2- Investors Mobilization
and selection

3- Implementation of the Strategy and investor Business
plan

- Negotiate binding commer,cfal agreements
- Complete Market analysis

- Organize Investors Forum

- Complete manufactul'iing I
distribution feasibility studies

- Call for Expression of Interest

- Finalize Technology Transfer and Licensing Agreement (TTLA)
- Support last mile distribution and testing solutions
- Conduct Investor due diligence
• Identify enabling
interventions

- Prepare and share product and education materials

- Develop short list of investors
- Demonstrat! the effectiveness of the product

- Sequence of interventions
- Develop long list of
investors

- Facilitate Business plan
development and submission

- Organize trainings on the use of the product
- Monitor progress
- Share best practices and lessons learned with investors
- Adjust country and portfolio strategies as necessary to achieve
targets

Cross-cutting: Awareness raising+ Advocacv for regu lations enforcement + Strat egic oartnershios wit h downstream actors
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AFLASAFE TECHNOLOGY TRANSFER AND
COMMERCIALISATION INITIATIVE (ADC)

flasafe

Safer food in Africa
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SENEGAL

•

Aflasafe SN01 launched Mar 2017
Manufacturer/Distributor: BAMTAARE
• --------,
Distribution points: Tanbacounda, Katrine,
Kaolack, Sedhiou and Fatick
Aflasafe-protected hectares: 24,800 *

BURKINA FASO

Aflasafe BF01 launched Jun 2018
Distributor: Elephant Vert
Distribution points: Bobo Dioulasso,
Ouagadougou
Aflasafe-protected hectares: 1,000
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THE GAMBIA
Afla safe SN01 launched Mar 2017
Manufacturer/Distributor. BAMTMRE •
• Af/asafe-protected hectares: 11 ,000
Distribution points: Banjul, North Bank,

*

Central River, West Coast Lower River Region
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Aflasafe product development

Allasale factory

~

Aflasafe distribution

KENYA

Aflasafe KE01 launched Oct 2016
• Manufacturer/Distributor: KALRO
• Distribution point: Machakos
Af/asafe-protected hectares:14,600

Aflasafe commercialised
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NIGERIA
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Af/asafe-protected hectares: 2,000*
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2013: Aflasafe TM commercialisation
begins
• Distributor: Harvestfield Industries Ltd
Distribution points: Ekiti. Niger, Ondo,
Abuja FCT, Osun, Kano,
Oyo, Jigawa, Ogun, Kaduna, Edo,
Katsina, Anambra, Zamfara, Imo,
Sokoto, Kwara, Gombe, Kebbi.
Bauchi
Aflasafe-protected hectares: 92,400 *

GHANA
Aflasafe GH02 launched June 2018
• Distributor: Macrofertil Ghana Limited
• Distribution points: Accra, Tamale
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Aflatoxins test results were below 4 parts per billion in all commercialisation countries
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WHAT HAVE WE LEARNED?

- This "Invisible problem" requires significant investment on public awareness
and the enforcement of appropriate policies
- The proof of concept in one country is essential but not sufficient to
demonstrate the value of the product in all countries.
- Timing of the investors forum: The demonstration at national level and the
development of the Business cases earlier in year 1 may positively affect the
success of investors mobilization
- Ownership of the Business planning by the investor: From the strategy to the
Business plan
QUESTIONS?
Management of the commercialization process: What is the right balance between the
Business Development and the scientific work?
How should business development approach differ between publicly funded innovations
with public health benefits and privately funded innovations?
What kind of institutional set up is required to sustain the gains and expand to other
products?

